Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial - Archive ouverte HAL Access content directly
Journal Articles International Journal of Radiation Oncology, Biology, Physics Year : 2010

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial

Nicolas Girard
  • Function : Author
F. Mornex
  • Function : Author
Nadine Bossard
M. Ychou
  • Function : Author
B. Chauffert
V. Wautot
  • Function : Author
No file

Dates and versions

hal-00698359 , version 1 (16-05-2012)

Identifiers

  • HAL Id : hal-00698359 , version 1

Cite

Nicolas Girard, F. Mornex, Nadine Bossard, M. Ychou, B. Chauffert, et al.. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial. International Journal of Radiation Oncology, Biology, Physics, 2010, 77(5), pp.1426-1432. ⟨hal-00698359⟩
76 View
0 Download

Share

Gmail Facebook X LinkedIn More